CD274 and triple-negative breast carcinoma: For example, stereotactic body radiotherapy enhances the antitumor effects of the anti-PD-L1 McAb durvalumab in patients with early-stage NSCLC [98], and the combination of McAb pembrolizumab and radiotherapy has shown promising activity in patients with triple-negative breast cancer [99].